ProPharma Unveils Prodigy: Groundbreaking Technology-Enabled Consulting Platform to Revolutionize Life Science Consulting Industry

ProPharma Group has introduced Prodigy, an end-to-end technology-enabled consulting platform as an evolution to their RCO delivery model. Whitepaper published alongside today's announcement details $5M+ investment and up to 50% improvement in speed, quality, and cost with new AI-enhanced solutions.

RALEIGH, N.C., Jan. 4, 2024 ProPharma Group, the world's largest Research Consulting Organization (RCO) and the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, has introduced Prodigy, an end-to-end technology-enabled consulting platform as an evolution to their RCO delivery model. By enhancing ProPharma's global RCO capability with AI and machine learning solutions, Prodigy bolsters ProPharma's ability to lead the industry in its journey from volume to value, where access to information, and the utility of technology and evidence continue to drive increased nuance and opportunity for innovators. This innovative development underscores ProPharma's commitment to driving change in the clinical research industry, with a focus on becoming an insights leader and providing friction-free and insightful experiences for their clients.

In a significant departure from traditional clinical research outsourcing (CRO) models, ProPharma's Prodigy platform introduces a suite of new features designed to meet the demands across the full lifecycle of drug and device development. Leveraging a forward-thinking, tech-enabled consulting mindset, Prodigy empowers researchers and sponsors with the tools needed to navigate the complex challenges associated with developing a winning clinical strategy.

Prodigy is a result of ProPharma's strategic investment of over $5 million in 2023 alone, reflecting the company's dedication to innovation in the life sciences industry. This new suite of features encompasses three core capabilities:

ProPharma has also published a whitepaper titled "Innovation and the Black Swan: the imperative of AI-enabled clinical research" alongside today's announcement. The whitepaper dives into how ProPharma's Prodigy platform addresses shortcomings of the CRO model with the new tech-enabled consulting platform. Given the explosive growth in the market, there's a strong need for new tech advancements, like Prodigy, to provide complementary technologies to support our operational ability to flex and align our delivery model to variations across innovator size and scope.

"At ProPharma, AI-first implies democratizing access to these new resources; transforming the fabric of our business and improving the ability of our teams to drive the future of science," says Mike Stomberg, CEO of ProPharma. "Prodigy is a testament to our commitment to navigate challenges within the life sciences industry, positioning ProPharma as a leader committed to innovation and marking a significant step forward in driving advancements in patient care through technology-enabled tools that provide sponsors a shared path to value."

To read ProPharma's full whitepaper, please visit https://www.propharmagroup.com/press/innovation-and-the-black-swan-prodigy-whitepaper?hs_preview=DnRydogY-151879336744

About ProPharma
For over 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world's largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners' most high-profile drug and device programs.

For more information about ProPharma, please visit: https://www.propharmagroup.com.

About Odyssey Investment Partners
Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends.

For more information about Odyssey, please visit: https://www.odysseyinvestment.com/.

ProPharma Media Inquiries and Contacts:

Zosya Popik
Vice President, Global Marketing
ProPharma
[email protected]

Jason Wakeford
Associate Partner
Clarity for ProPharma
[email protected]